First-in-human Trial of CRISPR Gene-editing ANGPTL3 Safely Lowered Cholesterol and Triglycerides
Key Points: CTX310 is a first-in-class in vivo CRISPR-Cas9 therapy designed to permanently disrupt hepatic ANGPTL3, a gene that regulates lipid metabolism. In the Phase 1 CRISP-ANGPTL3 trial, a single…
Tirzepatide Lowers MACE vs Dulaglutide in SURPASS-CVOT Patients With Heart Failure
Key Points In SURPASS-CVOT, tirzepatide was previously shown to be non-inferior to dulaglutide for 3-point major adverse cardiovascular events (MACE-3) in adults with type 2 diabetes and atherosclerotic cardiovascular disease,…
DAPT-MVD: Extended DAPT reduces MACCE in patients with multi-vessel disease after DES
Key Points: The optimal duration and choice of dual antiplatelet therapy (DAPT) after one year for patients with multivessel disease who undergo percutaneous coronary intervention (PCI) (MVD) remains uncertain. The…
NOAC Monotherapy Non-Inferior to Combination Therapy for Net Adverse Clinical events in AF Patients Post–DES: ADAPT AF-DES Trial
Key Points The ADAPT AF-DES randomized trial compared NOAC monotherapy (apixaban or rivaroxaban) versus NOAC plus clopidogrel in atrial fibrillation (AF) patients who had undergone drug-eluting stent (DES) implantation ≥1…
Prasugrel Might be a Better Choice than Ticagrelor For DAPT after PCI for Patients with Diabetes and MVD: The TUXEDO-2 Trial
Key Points TUXEDO-2 directly compared ticagrelor vs prasugrel based DAPT in 1,800 patients with diabetes and multivessel coronary artery disease (MVD) undergoing PCI with drug-eluting stents. Conducted across 66 centers…
POLY-HF: Polypill for HFrEF Shows Promise in Reducing Medication Burden Among Underserved Patients
Key Points: Patients with heart failure with reduced ejection fraction (HFrEF) often face a high daily pill burden, contributing to poor adherence to guideline-directed medical therapy (GDMT). The POLY-HF study…
CorCMR: Stress Cardiac MRI Uncovers Hidden Angina and Improves Quality of Life in Patients Without Obstructive Coronary Disease
Key Points: Stress cardiac MRI (CMR) enhanced diagnostic accuracy for patients with angina but no obstructive coronary artery disease, identifying microvascular angina often missed by standard angiography. In the CorCMR…
CELEBRATE: Early Pre-hospital Subcutaneous Zalunfiban Improves Coronary Patency and Outcomes in STEMI Without Increasing Severe Bleeding
Key Points: Early pre-hospital administration of subcutaneous zalunfiban improved coronary patency and reduced composite adverse outcomes at 30 days in patients with STEMI. Zalunfiban reduced the likelihood of a worse…
Family-Based Intervention Reduced Blood Pressure in Adults in Rural China: The Healthy Family Program
Key Points: A community- and family-based intervention can reduce systolic blood pressure (SBP) across both hypertensive and normotensive adults in rural Chinese villages. The intervention blends lifestyle education, low-sodium salt…
DASH Diet Patterned Groceries Help Reduce Blood Pressure in Black Adults: The GOFRESH Trial
Key Points: The GOFRESH trial, a parallel-group randomized study, was conducted to determine the effects of low sodium-DASH groceries on systolic BP. Home-delivered groceries selected to follow a DASH diet…
BETTER-BP: Offering Cash Incentives Improves Anti-Hypertensive Medication Adherence, But Not Blood Pressure Control
Key Points: Adherence to antihypertensive medications remains a persistent challenge in clinical practice. The BETTER-BP trial randomized participants with poorly controlled hypertension to one of two arms: (1) a financial…
FAVOR IV-QVAS: Angio-FFR–Guided CABG During Valve Surgery Improves Outcomes
Key Points: The FAVOR IV-QVAS trial tested the hypothesis physiology-guided coronary artery bypass grafting (CABG) using angiography-derived fractional flow reserve (Angio-FFR) improves outcomes compared with conventional angiography-guided CABG in patients…
ABLATION Trial – Biatrial Ablation During Mitral Valve Surgery Better than LA Ablation Alone
Key Points: Persistent atrial fibrillation (AF) is common among patients with rheumatic mitral valve disease undergoing surgery, but the optimal surgical ablation strategy remains uncertain. In this multicenter randomized trial…
PCSK9-inhibitors Do Not Reduce Early Cardiac Allograft Vasculopathy: The CAVIAR Trial
Key Points The CAVIAR trial enrolled recent heart transplant recipients to receive either receive alirocumab 150 mg subcutaneously every 2 weeks or placebo, in addition to rosuvastatin (target 20 mg…
Oral KCl Supplementation Lowers Sodium Load and Blood Pressure in Hypertension: SSTT Trial
Key Points The See Sodium to Treat (SSTT) Trial tested whether isolated oral KCl intake without sodium reduction could lower body Na⁺ content and blood pressure in patients with hypertension.…
Daily Coffee Lowers AFib Recurrence After Cardioversion: The DECAF Trial
Key Points The Does Eliminating Coffee Avoid Fibrillation (DECAF) trial is the first randomized study to directly test whether coffee consumption influences atrial fibrillation (AF) recurrence. Among 200 patients post-cardioversion,…
A Liberal Transfusion Strategy Does Not Significantly Reduce MACE vs a Restrictive Strategy in High Cardiac Risk Patients: The TOP Trial
Key Points: In patients at high cardiac risk undergoing major vascular or general surgery and developing postoperative anemia, a liberal transfusion strategy (Hb < 10) did not significantly reduce 90-day…
Two Factor XI Antibodies For the Prevention of Post- operative VTE: Results from ROXI-VTE-I and ROXI-VTE-II Trials
Key Points: ROXI-VTE-I and ROXI-VTE-II evaluated two distinct factor XI monoclonal antibodies REGN9933A2 and REGN7508Cat, for prevention of venous thromboembolism (VTE) after elective knee replacement. The Apple II domain-binding antibody…
Early Surgery Provides Durable Survival Advantage in Asymptomatic Severe Aortic Stenosis: Final 10-Year Outcomes from the RECOVERY Trial
Key Points: Over a decade of follow-up, early surgical aortic valve replacement (AVR) continued to confer a substantial survival advantage over conservative management in asymptomatic patients with very severe aortic…
OPTIMA-AF Trial – One-month Dual Therapy After PCI Non-inferior to 12 Months, With Lower Bleeding in AF Patients
Key Points: • In patients with atrial fibrillation (AF) undergoing PCI, prolonged dual antithrombotic therapy increases bleeding risk. • OPTIMA-AF tested whether one-month of dual therapy (DOAC + P2Y12i) followed…